1 Big Biotech Winner and 1 Loser Down 22% After Earnings

Human Genome Sciences, Inc. (NASDAQ:HGSI) reported its results for the third quarter.  Loss widened to $88.4 million (45 cents per diluted share) from $40.9 million (loss of 22 cents per share) in the same quarter a year earlier. Revenue fell 33% to $34 million from the year earlier quarter. HGSI fell short of the mean analyst estimate of a loss of 39 cents per share. It fell short of the average revenue estimate of $37.3 million.

“We are seeing solid progress in the trial and adoption of BENLYSTA treatment for systemic lupus by rheumatologists in the United States,” said H. Thomas Watkins, President and Chief Executive Officer. “The number of key accounts that have begun to order BENLYSTA has increased substantially. The number of countries in which BENLYSTA is available continues to increase. We and GSK look forward to making BENLYSTA available around the world.”

Competitors to Watch: GlaxoSmithKline plc (NYSE:GSK), Immunomedics, Inc. (NASDAQ:IMMU), Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA), Amgen, Inc. (NASDAQ:AMGN), Biogen Idec Inc. (NASDAQ:BIIB), AstraZeneca plc (NYSE:AZN), Merck & Co., Inc. (NYSE:MRK), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), and Peregrine Pharmaceuticals (NASDAQ:PPHM).

Amgen Inc. (NASDAQ:AMGN) reported its results for the third quarter. Net income for Amgen Inc. fell to $454 million (50 cents per share) vs. $1.24 billion ($1.28 per share) a year earlier. This is a decline of 63.3% from the year earlier quarter. Revenue rose 3.4% to $3.94 billion from the year earlier quarter. AMGN reported adjusted net income of $1.40 per share. By that measure, the company beat the mean estimate of $1.26 per share. Analysts were expecting revenue of $3.87 billion.

“Our business has performed well this year, which has given us confidence to increase our full-year revenue and EPS guidance,” said Kevin Sharer, chairman & CEO. “We are also confident in our outlook and long-term value and intend to accelerate our stock repurchase.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Biogen Idec Inc. (NASDAQ:BIIB), GlaxoSmithKline plc (NYSE:GSK), Affymax, Inc. (NASDAQ:AFFY), Genzyme Corporation (NASDAQ:GENZ), Roche Holding Ltd. (RHHBY), Novartis AG (NYSE:NVS), 3SBio Inc. (NASDAQ:SSRX), and NPS Pharmaceuticals, Inc. (NASDAQ:NPSP).